Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0000875320-26-000092 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | 2026-02-18 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $483.75 | -2,964 | 38.3K | -7% | -$1.43M | |
| 2026-02-19 | 2026-02-17 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | A - Grant | $0.00 | +8,269 | 41.3K | +25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-18 | F | D | 2,964 | $483.75 | 38,344 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-17 | A | A | 8,269 | $0.00 | 41,308 | D | — | — | (F1) Restricted stock unit award that fully vested upon grant. |